Efficacy of domperidone and pyridostigmine in the treatment of patients with functional dyspepsia: A randomized clinical trial

Govaresh

Volumn 17, Issue 1, 2012, Pages 7-12

  Shokry Shirvani, Javad ^a   Taheri, Hassan ^a   Shad, Esraphil ^a   Bijani, Ali ^a   Kashifard, Mehrdad ^a  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Domperidone; Functional dyspepsia; Pyridostigmine

Indexed keywords

EID: 84861849441     PISSN: 15607186     EISSN: 2008756X     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, Stanghellini V. Functional gastroduodenal disorders. Gastroenterology 2006 :130:1466-79.
2. Kurata JH, Nogawa AN, Everhart JE. A prospective study of dyspepsia in primarycare. Dig Dis Sci 2002;47:797-803.
3. Barzkar M, Pourhoseingholi MA, Habibi M, Moghimi-Dehkordi B, Safaee A, Pourhoseingholi A, et al. Uninvestigated dyspepsia and its related factors in an Iranian community. Saudi Med J 2009;30:397-402.
4. Richter JE. Dyspepsia: organic causes and differential characteristics from functional dyspepsia. Scand J Gastroenterol Suppl 1991;182:11-6.
5. Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005;129:1756-80. (Pubitemid 41597412)
6. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ 3rd. Dyspepsia and dyspepsia subgroups: a population-based study. Gastroenterology 1992;102:1259-68.
7. Kwan AC, Bao TN, Chakkaphak S, Chang FY, Ke MY, Law NM, et al.Validation of Rome II criteria for functional gastrointestinal disorders byfactor analysis of symptoms in Asian patient sample. J Gastroenterol Hepatol 2003;18:796-802. (Pubitemid 36936571)
8. Hiyama T, Yoshihara M, Matsuo K, Kusunoki H, Kamada T, Ito M, etal. Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia. J Gastroenterol Hepatol 2007; 22:304-10. (Pubitemid 46238756)
9. Tack J. Prokinetics and fundic relaxants in upper functional GI disorders.Curr Opin Pharmacol 2008;8:690-6.
10. Tack J, Van Den Elzen B, Tytgat G, Wajs E, Van Nueten L, De Ridder F, et al. A placebo-controlled trial of the 5-HT1A agonist R-137696 on symptoms, visceral hypersensitivity and on impaired accommodation in functional dyspepsia. Neurogastroenterol Motil 2009; 21:619-26.
11. Otaka M, Jin M, Odashima M, Matsuhashi T, Wada I, Horikawa Y, et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005;21:42-6. (Pubitemid 40806580)
12. Accarino A, Perez F, Azpiroz F, Quiroga S, Malagelada JR. Intestinal gas and bloating: effect of prokinetic stimulation. Am J Gastroenterol 2008;103:2036-42.
13. Talley NJ. Review article: functional dyspepsia-should treatment be targeted on disturbed physiology? Aliment Pharmacol Ther 1995;9:107-15.
14. Tack J, Lee KJ. Pathophysiology and treatment of functional dyspepsia. J Clin Gastroenterol 2005;39:S211-16. (Pubitemid 44638349)
15. Karamanolis G, Caenepeel P, Arts J, Tack J. Association of the predominant symptom with clinical characteristics and pathophysiological mechanisms in functional dyspepsia. Gastroenterology 2006;130;:296-303. (Pubitemid 43202029)
16. Dinan TG, Scott LV, Brady D, McNamara D, Keeling PW. Altered hypothalamic cholinergic responses in patients with nonulcer dyspepsia: a study of pyridostigmine-stimulated growth hormone release. Am J Gastroenterol 2002;97:1937-40.
17. O'Dea CJ, Brookes JH, Wattchow DA. The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine. Colorectal Dis 2010;12:540-8.
18. Bharucha AE, Low PA, Camilleri M, Burton D, Gehrking TL, Zinsmeister AR. Pilot study of pyridostigmine in constipated patients with autonomic neuropathy. Clin Auton Res 2008;18:194-202.